The global ulcerative colitis market size was estimated to be USD 0.636 billion in 2023 and is expected to reach USD 1.27 billion by 2034 with a CAGR of 6.52% during the forecast period 2024-2034. The market will grow as a result of factors such as the rising prevalence of ulcerative colitis, improvements in medical research and technology, increased awareness and early diagnosis, rising pipeline developments and drug approvals, expanding government initiatives, and partnerships and collaborations.
Globally increasing instances of ulcerative colitis are among the key factors propelling the market. Effective treatment solutions are in high demand due to the rising number of instances of UC caused by dietary changes, environmental factors, and lifestyle modifications. Novel therapeutics and diagnostic techniques for ulcerative colitis have been developed as a result of ongoing breakthroughs in medical research and technology. The availability of novel therapeutic options such as biologics and targeted treatments is propelling the market's expansion. For instance, in May 2023, the FDA approved Takeda Pharmaceutical Company Limited's Entyvio (vedolizumab) for the maintenance of clinical remission in adult patients with moderate to severe ulcerative colitis who responded to Entyvio induction therapy.
By disease type, the pancolitis or universal colitis segment accounted for the highest revenue-grossing segment in the global ulcerative colitis market in 2023 owing to the widespread prevalence of severe and extensive inflammation across the entire colon and rectum, prompting an increased demand for advanced therapeutic interventions and targeted treatments tailored to address the specific challenges associated with this severe form of ulcerative colitis. For instance, in October 2023, the FDA approved AbbVie Inc.'s product Skyrizi (risankizumab-rzaa) to treat individuals with moderate to severe ulcerative colitis who have not responded well to traditional therapy. Additionally, the ulcerative proctitis segment is predicted to grow at the fastest CAGR during the forecast period owing to the increased awareness of less severe types of ulcerative colitis and a greater focus on early identification and treatment.
By drug type, the anti-inflammatory drugs segment accounted for the highest revenue-grossing segment in the global ulcerative colitis market in 2023 owing to the widespread adoption as primary therapeutic agents for managing inflammation and symptoms associated with the condition, thereby driving robust market demand and revenue generation. For instance, n December 2022, Pfizer Inc. and MorphoSys AG entered into a collaborative agreement to develop and market antibodies targeting interleukin-23 (IL-23) for a range of autoimmune illnesses, including ulcerative colitis. Additionally, the anti-TNF biologics segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing efficacy in treating ulcerative colitis by targeting specific inflammatory pathways, driving heightened demand for these advanced and targeted therapies.
By distribution channel, the hospital pharmacies segment accounted for the highest revenue-grossing segment in the global ulcerative colitis market in 2023 owing to the centralized and efficient distribution channels within hospital settings, facilitating the accessibility and prompt availability of prescribed medications for patients with ulcerative colitis. For instance, in August 2022, the FDA approved Eli Lilly and Company's Olumiant (baricitinib) for the treatment of people with moderately to severely active ulcerative colitis who have not reacted well to TNF blockers or conventional therapy. Additionally, the online pharmacies segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing trend of digital healthcare, convenience in medication procurement, and the expanding consumer preference for online platforms for purchasing ulcerative colitis medications.
North American region is anticipated to have the highest revenue share during the forecast period owing to the well-established healthcare infrastructure, high prevalence of ulcerative colitis, and the rapid adoption of advanced treatment modalities in the region. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the increasing awareness, rising incidence of ulcerative colitis, improved healthcare infrastructure, and a growing focus on accessible and innovative treatment options in the region. For instance, in May 2023, the FDA approved Zeposia (daclizumab) by Bristol Myers Squibb Company to treat adult patients with moderately to severely active ulcerative colitis who have not responded well to standard therapy with TNF blockers.
This extensive research report concentrates on the size and projections of the global and regional markets from 2023 to 2034.
Globally increasing instances of ulcerative colitis are among the key factors propelling the market. Effective treatment solutions are in high demand due to the rising number of instances of UC caused by dietary changes, environmental factors, and lifestyle modifications. Novel therapeutics and diagnostic techniques for ulcerative colitis have been developed as a result of ongoing breakthroughs in medical research and technology. The availability of novel therapeutic options such as biologics and targeted treatments is propelling the market's expansion. For instance, in May 2023, the FDA approved Takeda Pharmaceutical Company Limited's Entyvio (vedolizumab) for the maintenance of clinical remission in adult patients with moderate to severe ulcerative colitis who responded to Entyvio induction therapy.
By disease type, the pancolitis or universal colitis segment accounted for the highest revenue-grossing segment in the global ulcerative colitis market in 2023 owing to the widespread prevalence of severe and extensive inflammation across the entire colon and rectum, prompting an increased demand for advanced therapeutic interventions and targeted treatments tailored to address the specific challenges associated with this severe form of ulcerative colitis. For instance, in October 2023, the FDA approved AbbVie Inc.'s product Skyrizi (risankizumab-rzaa) to treat individuals with moderate to severe ulcerative colitis who have not responded well to traditional therapy. Additionally, the ulcerative proctitis segment is predicted to grow at the fastest CAGR during the forecast period owing to the increased awareness of less severe types of ulcerative colitis and a greater focus on early identification and treatment.
By drug type, the anti-inflammatory drugs segment accounted for the highest revenue-grossing segment in the global ulcerative colitis market in 2023 owing to the widespread adoption as primary therapeutic agents for managing inflammation and symptoms associated with the condition, thereby driving robust market demand and revenue generation. For instance, n December 2022, Pfizer Inc. and MorphoSys AG entered into a collaborative agreement to develop and market antibodies targeting interleukin-23 (IL-23) for a range of autoimmune illnesses, including ulcerative colitis. Additionally, the anti-TNF biologics segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing efficacy in treating ulcerative colitis by targeting specific inflammatory pathways, driving heightened demand for these advanced and targeted therapies.
By distribution channel, the hospital pharmacies segment accounted for the highest revenue-grossing segment in the global ulcerative colitis market in 2023 owing to the centralized and efficient distribution channels within hospital settings, facilitating the accessibility and prompt availability of prescribed medications for patients with ulcerative colitis. For instance, in August 2022, the FDA approved Eli Lilly and Company's Olumiant (baricitinib) for the treatment of people with moderately to severely active ulcerative colitis who have not reacted well to TNF blockers or conventional therapy. Additionally, the online pharmacies segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing trend of digital healthcare, convenience in medication procurement, and the expanding consumer preference for online platforms for purchasing ulcerative colitis medications.
North American region is anticipated to have the highest revenue share during the forecast period owing to the well-established healthcare infrastructure, high prevalence of ulcerative colitis, and the rapid adoption of advanced treatment modalities in the region. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the increasing awareness, rising incidence of ulcerative colitis, improved healthcare infrastructure, and a growing focus on accessible and innovative treatment options in the region. For instance, in May 2023, the FDA approved Zeposia (daclizumab) by Bristol Myers Squibb Company to treat adult patients with moderately to severely active ulcerative colitis who have not responded well to standard therapy with TNF blockers.
This extensive research report concentrates on the size and projections of the global and regional markets from 2023 to 2034.
Report Scope:
- Base Year: 2023
- Forecast Period: 2024-2034
Study Coverage
- Market Forecast by Disease Type, Drug Type, and Distribution Channel
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of the Top 10+ Major Market Players
- 20% Free Customization Available to Meet Your Exact Requirement.
Segmentation: Ulcerative Colitis Market Report 2023 - 2034
Ulcerative Colitis Market Analysis & Forecast by Disease Type 2023 - 2034 (Revenue USD Bn)
- Ulcerative Proctitis
- Proctosigmoiditis
- Left-sided Colitis
- Pancolitis or Universal Colitis
- Fulminant Colitis
Ulcerative Colitis Market Analysis & Forecast by Drug Type 2023 - 2034 (Revenue USD Bn)
- Anti-inflammatory drugs
- Anti-TNF biologics
- Immunosuppressants
- Calcineurin Inhibitors
- Other Drug Types
Ulcerative Colitis Market Analysis & Forecast by Distribution Channel 2023 - 2034 (Revenue USD Bn)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Ulcerative Colitis Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Ulcerative Colitis Market: DIsease Type Estimates & Trend Analysis
8. Ulcerative Colitis Market: Drug Type Estimates & Trend Analysis
9. Ulcerative Colitis Market: Distribution Channel Estimates & Trend Analysis
10. Regional Market Analysis
11. North America Ulcerative Colitis Market
12. Europe Ulcerative Colitis Market
13. Asia Pacific Ulcerative Colitis Market
14. Latin America Ulcerative Colitis Market
15. MEA Ulcerative Colitis Market
16. Competitor Analysis
17. Company Profiles
Companies Mentioned
- Eli Lilly and Company
- Bristol Myers Squibb Company
- GlaxoSmithKline plc
- Novartis AG
- Celgene Corporation (acquired by Bristol Myers Squibb)
- UCB S.A.
- Astellas Pharma Inc.
- Boehringer Ingelheim International GmbH
- AstraZeneca PLC
- Janssen Biotech Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | March 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 0.64 Billion |
| Forecasted Market Value ( USD | $ 1.27 Billion |
| Compound Annual Growth Rate | 6.5% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
